Back to Search
Start Over
Influence of the CB 1 and CB 2 cannabinoid receptor ligands on the activity of atypical antidepressant drugs in the behavioural tests in mice.
- Source :
-
Pharmacology, biochemistry, and behavior [Pharmacol Biochem Behav] 2020 Jan; Vol. 188, pp. 172833. Date of Electronic Publication: 2019 Nov 27. - Publication Year :
- 2020
-
Abstract
- Available data support the notion that cannabinoids, whose therapeutic value is limited due to severe adverse reactions, could be beneficial as adjunctive agents in the management of mood disorders. Polytherapy, which is superior to monotherapy in the terms of effectiveness, usually requires lower doses of the individual components. Therefore, the main objective of our study was to determine whether administration of cannabinoid (CB) receptor ligands would enhance the antidepressant activity of atypical antidepressant drugs, i.e. agomelatine and tianeptine. To evaluate the antidepressant-like potential of the tested combinations, the mouse forced swim test (FST) and the tail suspension test (TST) were used. The HPLC method was applied to assess the brain levels of agomelatine and tianeptine. Both behavioural tests demonstrated that per se an ineffective intraperitoneal dose of oleamide (CB <subscript>1</subscript> receptor agonist, 5 mg/kg) potentiated the anti-immobility activity of tianeptine (15 mg/kg), whereas AM251 (CB <subscript>1</subscript> receptor inverse agonist/antagonist, 0.25 mg/kg) enhanced the antidepressant effects of tianeptine and agomelatine (20 mg/kg). Intraperitoneal co-administration of per se inactive doses of AM630 (CB <subscript>2</subscript> receptor inverse agonist/antagonist) and agomelatine or tianeptine significantly reduced the immobility time of animals only in the FST. CB receptor ligands did not affect the brain levels of the tested atypical antidepressants. In summary, the outcomes of the present study showed that activation and inhibition of CB <subscript>1</subscript> receptors as well as inhibition of CB <subscript>2</subscript> receptors may increase the antidepressant activity of tianeptine, whereas only inhibition of CB <subscript>1</subscript> and CB <subscript>2</subscript> receptors has a potential to augment the antidepressant activity of agomelatine.<br /> (Copyright © 2019. Published by Elsevier Inc.)
- Subjects :
- Acetamides pharmacology
Acetamides therapeutic use
Animals
Antidepressive Agents, Tricyclic pharmacology
Depression drug therapy
Depression psychology
Hindlimb Suspension methods
Hindlimb Suspension psychology
Hypnotics and Sedatives pharmacology
Hypnotics and Sedatives therapeutic use
Ligands
Locomotion physiology
Male
Mice
Receptor, Cannabinoid, CB1 agonists
Receptor, Cannabinoid, CB1 antagonists & inhibitors
Receptor, Cannabinoid, CB2 agonists
Receptor, Cannabinoid, CB2 antagonists & inhibitors
Swimming psychology
Thiazepines pharmacology
Thiazepines therapeutic use
Antidepressive Agents, Tricyclic therapeutic use
Depression metabolism
Locomotion drug effects
Receptor, Cannabinoid, CB1 metabolism
Receptor, Cannabinoid, CB2 metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1873-5177
- Volume :
- 188
- Database :
- MEDLINE
- Journal :
- Pharmacology, biochemistry, and behavior
- Publication Type :
- Academic Journal
- Accession number :
- 31785246
- Full Text :
- https://doi.org/10.1016/j.pbb.2019.172833